Regeneron Pharmaceuticals, Inc. (REGN) Shares Bought by Royal Bank of Canada

Royal Bank of Canada grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 67,464 shares of the biopharmaceutical company’s stock after purchasing an additional 2,802 shares during the period. Royal Bank of Canada owned about 0.06% of Regeneron Pharmaceuticals worth $33,135,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in REGN. FMR LLC increased its holdings in Regeneron Pharmaceuticals by 6.3% during the second quarter. FMR LLC now owns 7,039,884 shares of the biopharmaceutical company’s stock worth $3,457,569,000 after buying an additional 416,192 shares during the last quarter. BlackRock Inc. increased its holdings in Regeneron Pharmaceuticals by 0.7% during the second quarter. BlackRock Inc. now owns 6,188,267 shares of the biopharmaceutical company’s stock worth $3,039,305,000 after buying an additional 41,406 shares during the last quarter. Vanguard Group Inc. increased its holdings in Regeneron Pharmaceuticals by 2.9% during the second quarter. Vanguard Group Inc. now owns 5,270,458 shares of the biopharmaceutical company’s stock worth $2,588,533,000 after buying an additional 148,962 shares during the last quarter. State Street Corp increased its holdings in Regeneron Pharmaceuticals by 4.3% during the first quarter. State Street Corp now owns 3,380,151 shares of the biopharmaceutical company’s stock worth $1,309,861,000 after buying an additional 139,602 shares during the last quarter. Finally, Artisan Partners Limited Partnership increased its holdings in Regeneron Pharmaceuticals by 1.5% during the second quarter. Artisan Partners Limited Partnership now owns 1,962,480 shares of the biopharmaceutical company’s stock worth $963,852,000 after buying an additional 29,252 shares during the last quarter. Institutional investors own 67.40% of the company’s stock.

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) opened at 445.68 on Tuesday. The stock’s 50 day moving average is $456.72 and its 200-day moving average is $455.81. Regeneron Pharmaceuticals, Inc. has a one year low of $325.35 and a one year high of $543.55. The company has a market cap of $47.26 billion, a PE ratio of 44.71 and a beta of 1.63.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.67 by $1.50. The firm had revenue of $1.47 billion for the quarter, compared to the consensus estimate of $1.36 billion. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The company’s quarterly revenue was up 21.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.82 EPS. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post $14.94 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by BBNS and is owned by of BBNS. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://baseballnewssource.com/markets/royal-bank-of-canada-buys-2802-shares-of-regeneron-pharmaceuticals-inc-regn/1698713.html.

A number of research firms recently issued reports on REGN. Piper Jaffray Companies raised their price objective on shares of Regeneron Pharmaceuticals from $446.00 to $557.00 and gave the stock an “overweight” rating in a report on Tuesday, June 20th. BMO Capital Markets set a $491.00 target price on shares of Regeneron Pharmaceuticals and gave the stock a “hold” rating in a research report on Thursday, August 3rd. Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and set a $472.00 target price (up previously from $469.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 9th. Jefferies Group LLC reiterated a “hold” rating and set a $471.00 target price (up previously from $418.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 9th. Finally, Leerink Swann reiterated an “outperform” rating and set a $580.00 target price (up previously from $573.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 9th. Three equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. Regeneron Pharmaceuticals presently has an average rating of “Hold” and an average price target of $489.92.

In other Regeneron Pharmaceuticals news, Director Charles A. Baker sold 2,000 shares of the company’s stock in a transaction dated Friday, September 29th. The stock was sold at an average price of $450.00, for a total transaction of $900,000.00. Following the sale, the director now owns 11,000 shares in the company, valued at approximately $4,950,000. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Robert E. Landry sold 189 shares of the company’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total value of $94,700.34. Following the sale, the chief financial officer now owns 10,099 shares in the company, valued at approximately $5,060,204.94. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 89,468 shares of company stock worth $42,312,448. 10.80% of the stock is owned by company insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Red Sox Waste Little Time in Firing John Farrell
Red Sox Waste Little Time in Firing John Farrell
Washington Nationals Sans Strasburg for Game 4 at Wrigley
Washington Nationals Sans Strasburg for Game 4 at Wrigley
Red Sox Beat Houston Sunday to Avoid Elimination
Red Sox Beat Houston Sunday to Avoid Elimination


Leave a Reply

 
© 2006-2017 BBNS.